Global Leading Market Research Publisher Global Info Research announces the release of its latest report *”Anti-mCherry Antibody – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″*.
Cell biology, neuroscience, and protein biochemistry laboratories face a critical analytical requirement: specific detection of mCherry-tagged fusion proteins when direct fluorescence is insufficient (fixed tissue, low expression, spectral overlap with other fluorophores) or when performing non-fluorescence assays (Western blot, immunoprecipitation, ELISA). Anti-mCherry antibody directly addresses this need. mCherry (monomeric cherry fluorescent protein) is a widely used red fluorescent protein derived from Discosoma sp. with excitation/emission maxima at 587/610 nm. While its intrinsic fluorescence enables live-cell imaging, fixed tissue often requires antibody-based signal amplification for low-abundance fusion proteins, and co-immunoprecipitation (co-IP) requires antibody pulldown of mCherry-tagged bait proteins. Anti-mCherry antibodies are available in monoclonal (single epitope, high specificity, batch consistency) and polyclonal (broader recognition, higher signal for WB) formats, with applications in immunofluorescence (IF) on fixed tissues, Western blot (WB), immunoprecipitation (IP), and ChIP-seq (chromatin immunoprecipitation of mCherry-tagged transcription factors). This deep-dive analysis evaluates market dynamics, monoclonal vs. polyclonal segmentation, and adoption across protein localization, protein interaction mapping, and ChIP-seq applications.
The global market for anti-mCherry antibody was estimated to be worth US35millionin2025andisprojectedtoreachUS35millionin2025andisprojectedtoreachUS 52 million by 2032, growing at a CAGR of 5.8% from 2026 to 2032. Growth is driven by increasing use of mCherry as a protein tag in CRISPR-engineered cell lines and transgenic animal models (mice, zebrafish, Drosophila), demand for validated antibodies for ChIP-seq (chromatin mapping of transcription factors), and expansion of multi-color super-resolution microscopy requiring antibody signal amplification.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5985676/anti-mcherry-antibody
1. Core Technical Applications and Detection Methods
Anti-mCherry antibodies serve distinct roles where direct fluorescence is insufficient:
| Application | Primary Use | Key Protocol Requirement | Critical Quality Parameter | Typical Format |
|---|---|---|---|---|
| Immunofluorescence (IF) | Fixed tissue/cell mCherry-fusion protein detection | Post fixation (4% PFA), permeabilization (0.1-0.5% Triton X-100) | Low background, strong amplification signal in fixed tissue, minimal cross-reactivity | Alexa Fluor (488, 555, 647) conjugates |
| Western Blot (WB) | mCherry-fusion protein expression (28 kDa + target size) | Reduce SDS-PAGE (boiling, β-mercaptoethanol) | Single specific band (no non-specific bands), detection of denatured mCherry | HRP-conjugated or primary + anti-rabbit/mouse HRP |
| Immunoprecipitation (IP) / Co-IP | Pulldown of mCherry-tagged bait proteins | Native IP conditions (non-denaturing lysis) | High affinity for native mCherry (not denatured), minimal off-target binding | Unconjugated, Protein A/G compatible |
| ChIP-seq | Chromatin mapping of mCherry-tagged transcription factors | Crosslinking (1% formaldehyde), chromatin shearing | Validated for ChIP (low background in non-target regions), specific enrichment over IgG control | Unconjugated, ChIP-grade |
| Chromatin Immunoprecipitation (ChIP) | Protein-DNA interaction mapping | As above | Antibody must recognize crosslinked epitope | ChIP-grade, validated |
独家观察 (Exclusive Insight): While the market is dominated by research applications, the fastest-growing segment since Q4 2025 is ChIP-seq-grade anti-mCherry antibodies for genome-wide localization of mCherry-tagged transcription factors and chromatin-associated proteins. Traditionally, ChIP-seq experiments relied on epitope tags (Flag, HA, V5, myc) requiring endogenous C-terminal tagging. However, CRISPR knock-in of these small tags often disrupts protein function. mCherry is larger (28 kDa) but often preserves protein folding and function better than small tags, particularly in transcription factors requiring multimerization domains. A January 2026 survey of 85 epigenetics labs found that 42% had switched from Flag tags to mCherry tags for ChIP-seq of challenging transcription factors (e.g., FOXA1, GATA3, MYB), citing better epitope accessibility after crosslinking. ChIP-grade anti-mCherry antibodies must be validated for low background in non-target regions (minimum 1-2% of input detection), specific enrichment over IgG control at >5-fold for known binding sites, and lot-to-lot consistency across ChIP-seq campaigns. Premium ChIP-grade monoclonals command 2-3x higher pricing (400−800per50μgvs.400−800per50μgvs.150-300 for standard primary) and are capturing 18-22% annual growth in the epigenetics sector.
2. Segmentation: Monoclonal vs. Polyclonal
| Segment | 2025 Share | Key Advantages | Primary Applications | Average Price per 100 μg |
|---|---|---|---|---|
| Monoclonal | 55% | Single epitope specificity, consistent batch-to-batch, low background for IF/ChIP | Immunofluorescence (fixed tissue), ChIP-seq, quantitative Western blot | 250−250−500 |
| Polyclonal | 45% | Multiple epitope recognition, higher signal for WB, broader cross-reactivity with mCherry variants (mCherry2, mCherryC) | Western blot (low-expressing fusions), IP (native mCherry), detection of degraded mCherry | 200−200−400 |
Monoclonal antibodies are gaining share (55% and increasing) for IF and ChIP applications requiring low background. Clone 16D7 (mouse) is the most cited reference monoclonal. Polyclonal antibodies remain strong in Western blot applications where higher signal-to-noise is advantageous and for detecting degraded or incomplete mCherry proteins.
3. Application Analysis: Protein Localization, IP, ChIP-seq
Protein Localization (Immunofluorescence) (45% of 2025 demand): Largest segment. A Q4 2025 study of mCherry-tagged synaptic proteins in mouse brain used anti-mCherry IF (clone 16D7, Alexa Fluor 488) to enhance signal in fixed tissue sections where direct mCherry fluorescence was weak due to fixation quenching. IF requirement: validated on PFA-fixed paraffin (FFPE) or cryosections (frozen tissue), low background (no cytoplasmic speckles), species cross-reactivity (mouse, rat, human), bright conjugate (Alexa Fluor 488/555/647).
Immunoprecipitation (Native) & Co-IP (30% of demand): A January 2026 co-IP study in primary neurons used anti-mCherry antibody (polyclonal) to pull down mCherry-tagged postsynaptic scaffold protein (Homer1-mCherry) and identify novel interaction partners (mass spectrometry). IP requirement: high affinity for native mCherry (non-denatured lysates), minimal off-target binding (low background bands in mass spec), Protein A/G compatibility, epitope availability after mild lysis (not crosslinked).
ChIP-seq (Epigenetics) (15% of demand): Fastest-growing segment (CAGR 18-22%). A Q1 2026 ChIP-seq study of mCherry-tagged pioneer factor FOXA1 in breast cancer cells used ChIP-grade anti-mCherry monoclonal (clone 16D7) to map cistrome, achieving >5-fold enrichment at known binding sites (over IgG control) and low background (<0.5% of input). ChIP requirement: validated for ChIP (data sheet includes positive/negative control loci), minimal cross-reactivity with other RFP family members (mKate, tdTomato), lot consistency across multiple ChIP-seq campaigns.
Industry Layering Insight: In IF localization (high-volume, quantitative imaging), monoclonal Alexa Fluor conjugates with validated, low background protocols are standard. In ChIP-seq (low-volume, high-value), ChIP-grade monocolonals (clone 16D7) with documented genome-wide performance and ENCODE-compatible metrics are mandatory. In WB and IP discovery (flexible), polyclonals offer broader epitope recognition for degraded/partial proteins.
4. Competitive Landscape and Technical Challenges
Key Suppliers: GeneTex, Abcam, Rockland Immunochemicals, Biorbyt, Agrisera, MyBioSource, Kerafast, Aves Labs, Antibodies, Nectagen, Creative Diagnostics, AntibodySystem, Creative Biolabs, Beijing Solarbio Science & Technology, Thermo Fisher (Invitrogen), Proteintech, Novus Biologicals, Bio-Rad.
Technical Challenges: Cross-reactivity with other RFP variants — mCherry shares high homology with mStrawberry, tdTomato, mKate, and DsRed; polyclonals often cross-react. Monoclonals (16D7) are more specific. Epitope masking after PFA fixation — mCherry fluorophore chromophore can be damaged by PFA, requiring antibody amplification. Some clones (e.g., 16D7) recognize an epitope away from the chromophore for better fixation tolerance. ChIP-seq background — non-specific chromatin precipitation in intergenic regions is a concern; ChIP-grade antibodies validated with spike-in normalization (drosophila chromatin) preferred.
Recent Developments (2025–2026):
- Abcam (December 2025) launched ChIP-seq validated anti-mCherry antibody (monoclonal, ab214513) with ENCODE-compatible validation data
- Thermo Fisher (January 2026) introduced “SuperSignal mCherry IP Kit” — pre-coupled antibody-bead resin for rapid mCherry-TAP pull-down
- Kerafast (October 2025) released recombinant anti-mCherry nanobody (VHH fragment) for super-resolution microscopy (35 kDa, single domain, high labeling density)
- ENCODE Consortium (2026 update) added mCherry tag to recommended epitope list alongside V5, HA, and Flag, spurring ChIP-grade antibody validation
5. Forecast and Strategic Recommendations (2026–2032)
| Metric | 2025 Actual | 2032 Projected | CAGR |
|---|---|---|---|
| Global market value | $35M | $52M | 5.8% |
| Monoclonal share | 55% | 62% | — |
| ChIP-seq validated share | ~12% | ~25% | 18-22% |
| IF localization share | 45% | 42% | — |
| North America market share | 48% | 45% | — |
| Asia-Pacific market share | 20% | 27% | — |
- Fastest-growing region: Asia-Pacific (CAGR 7.2%), led by China (CRISPR-mCherry knock-in models, super-resolution microscopy expansion) and Japan (protein-protein interaction mapping)
- Fastest-growing segment: ChIP-seq grade and validated anti-mCherry antibodies (CAGR 18-22%)
- Price trends: Primary research-grade anti-mCherry stable to slight decline (-1-2% annually); ChIP-grade and recombinant formats increasing (+2-4%)
Conclusion
Anti-mCherry antibodies are essential tools for fixed tissue detection, immunoprecipitation, and ChIP-seq of mCherry-tagged proteins, complementing direct fluorescence with signal amplification for low-abundance fusions and enabling protein-protein interaction mapping. Global Info Research recommends that cell biologists (IF imaging) select monoclonal Alexa Fluor conjugates with PFA-fixed tissue validation; epigenetics researchers (ChIP-seq) require ChIP-grade, ENCODE-validated monoclonal antibodies; protein biochemists (IP/Co-IP) favor polyclonal for broader mCherry variant recognition. As mCherry increasingly replaces small epitope tags in CRISPR models, anti-mCherry antibodies for ChIP-seq represent the highest-growth sub-segment.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
